At midday we can report on several great releases from key penny stocks that are likely to have a positive impact on share price today and for the next few days.
ForeverGreen Worldwide Corporation (OTCBB: FVRG)
Today’s news for FVRG: FG Xpress Experiencing Robust Sales
Although a light trader, this release came out midday today and is likely to generate some traction if it gets read. The Company’s shares trade lightly, but Friday’s close of $0.78 still holding firm in trading today.
Here is more from that release:
ForeverGreen Worldwide Corporation (OTCBB:FVRG), a leading provider of nutritional foods and other healthy products, today announced increasing sales for the FG Xpress product brand. Sales of the high margin FG Xpress brand increased 19.3% for July 2013 when compared to June 2013 and now account for 52% of overall sales.
Ron Williams, CEO, stated, “It is rewarding to see our recently introduced products continuing to be so favorably received by the public. For July, we had over 2,050 new customers and expect to exceed $1 million in monthly sales, just from FG Xpress, by the beginning of Q4. There appears to be few limits to our future growth, as we now have a solid product mix, the right layers of management to interface with an expanding customer and distributor base, and a product brand which can be sold virtually anywhere in the world. We are experiencing historic growth rates that we believe are just beginning. We anticipate escalating sales to levels several times higher during the next 12 months.”
ZIM Corporation (OTCBB: ZIMCF)
Today ZIMCF issued a release with the headline: ZIM Corporation reports first quarter 2014 financial results
While the release discusses an increase in the net loss year to year, the Company does report they have sufficient cash on hand:
“ZIM had cash and cash equivalents of $1,258,338 at June 30, 2013 as compared to cash and cash equivalents of $1,591,507 at March 31, 2013.”
Furthermore, the President and CEO gave this explanation of the issues: “As previously reported – our revenues have been impacted by project delays related to our enterprise database software and consulting services” said Dr. Michael Cowpland, President and CEO of Zim.”We are making good progress with resolving these delays and anticipate delivering these projects throughout the remainder of this fiscal year”
This is an occasional trader, although it did have a nearly three million share trade day back on July 22nd.
MRI Interventions, Inc. (OTCQB: MRIC)
Here’s another release that came out during the trading day this morning: MRI Interventions’ ClearPoint System Enables Precise Delivery of Promising Investigational Gene Therapy in Parkinson’s Disease Phase I Clinical Trial
Share responded immediately and are up four cents at $1.19. Volume is light, but there is a momentum on the buy side today.
Here is more from that release:
MRI Interventions, Inc. (OTCQB: MRIC) today announced treatment of the first patient in a Phase I clinical trial utilizing uniQure B.V.’s glial cell line-derived neurotrophic factor (GDNF) for treatment of Parkinson’s disease. This gene therapy holds promise in the battle against the degenerative and debilitating disorder, which affects 1.5 million people in the United States. MRI Interventions’ ClearPoint Neuro Intervention System is being used in the clinical trial to enable direct infusion of the gene therapy into an area of the brain affected by Parkinson’s disease.
Dr. Krystof Bankiewicz, MD, PhD at University of California, San Francisco (UCSF), and Dr. John D. Heiss, MD at the National Institute for Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), are leading the trial. uniQure B.V., a leader in human gene therapy, is providing the GDNF gene. uniQure made headlines last November by receiving regulatory approval in Europe of a first-in-class gene therapy to treat orphan diseases.
The hypothesis of the Parkinson’s disease trial is that GDNF’s neuro-regenerative and protective properties may protect and strengthen brain cells that produce dopamine, a chemical that affects brain function. In Parkinson’s disease, dopamine production is reduced in an area of the brain responsible for movement, which leads to the debilitating symptoms experienced by many patients with the disease. The affected area is a tiny spot located deep within the brain, and the ClearPoint System provides the visualization and precision necessary to deliver a desired amount of the gene therapy directly to this very small target without disrupting other critical neurological structures in the process.
Goldrich Mining Company (OTCBB: GRMC) (OTCQB: GRMC)
Goldrich issued this at about the open this morning: Goldrich Mining Further Strengthens Board of Directors
Thus far there has been no trading although last week saw some movement in shares. Board releases sometimes create less interest than more substantive releases. That said, these are two extraordinarily talented and experienced miners added to the board.
Here is a bit about each of the two new members as stated in the release:
Mr. Mendham brings over 25 years of mining experience in operations, technical work, and mining finance for both junior and large mining companies, including BHP, Rio Tinto, Lihir Gold, Bond Corporation, and Queensland Nickel. He is currently Vice President of Operations and Project Development for RH Mining Resources Ltd., a Hong Kong based mineral development company. He also previously worked as Director Technical Services with Regent Pacific Group, a prominent Hong Kong investment group involved in mineral resources related corporate transactions and equity capital markets.
Mr. Mendham is the Chairman of the Australasian Institute of Mining and Metallurgy Hong Kong branch. He received a Bachelor of Mine Engineering from the University of New South Wales, a Graduate Diploma in Finance from the Securities Institute of Australia, and holds Mine Manager Certificates in Australia for both New South Wales and Western Australia.
Mr. Vincent has over 30 years of experience as a finance specialist. He has held a range of positions with various companies including Moore Juran and Co., Miller and Schroeder Financial, Allison Williams Company, Piper Jaffray, and Northland Securities Inc. His roles have included metals distribution, debt instrument structuring, and private equity financing.
Most recently Mr. Vincent has raised capital for companies developing the copper-nickel mining district of northeastern Minnesota. He has completed strategic equity investments for Duluth Metals Ltd., Franconia Minerals and Encampment Minerals. He also completed a private placement financing for Goldrich in 2010. Mr. Vincent received a Bachelor’s degree from Boston College.
EnerJex Resources, Inc. (OTCQB: ENRJ)
This came out near the open today: EnerJex Resources Announces Financial Results for the Second Quarter Ended June 30, 2013, Including a 31% Increase in Adjusted EBITDA
Let’s bullet point some of this news…
Highlights for the second quarter include the following:
- Production of 23,857 barrels of oil, a 11% increase compared to the prior year excluding production from certain properties that were assigned to outside general partners upon the dissolution of Rantoul Partners at the end of 2012.
- Revenue of $2.2 million, a 16% increase compared to the prior year excluding revenue from certain properties that were assigned to outside general partners upon the dissolution of Rantoul Partners at the end of 2012.
- Operating expenses of $31.52 per net barrel of oil produced, a 1% decrease compared to the prior year.
- Adjusted earnings before interest, income tax, depriciation and amortization (“EBITDA”) of $864,515, a 31% increase compared to the prior year.
- Completion of drilling 5 new oil wells and 5 new secondary recovery water injection wells in EnerJex’s Mississippian Project located in Southeast Kansas with a 100% success rate.
- Completion of drilling 8 new oil wells and 8 new secondary recovery water injection wells in the Company’s Cherokee Project located in Eastern Kansas with a 100% success rate.